Skip to main content
Equibles
HRTX logo

HRTX · Heron Therapeutics, Inc. /De/ · Webcasts, Transcripts & Audio

Track HRTX — free

Use HRTX with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research HRTX.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$0.37 +0.02 (+6.44%) At close · Oct 5
Russell 2000 member Rebalance outlook locked
Market Cap
$55.85M
Shares
189.85M
Volume · Oct 5 2.94M Avg daily vol (3M) 2.59M

Heron Therapeutics, Inc. Webcasts

Earnings calls, investor updates, investor days and conferences for Heron Therapeutics, Inc. (HRTX), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.

Pull transcripts and briefs through the earnings call transcript API or MCP →

Revenue & result across quarters

Revenue Net income YoY up YoY down artefacts
▲23.1% $27.63M −$56.36M '22 Q2 22-08-09 ▲14.3% $26.56M −$41.91M '22 Q3 22-11-08 ▲26.3% $29.61M −$32.77M '23 Q1 23-05-11 ▲15% $31.76M −$42.06M '23 Q2 23-08-14 ▲18.4% $31.43M −$25.01M '23 Q3 23-11-14 ▲14% $34.23M −$10.72M '23 Q4 24-03-12 ▲17.1% $34.67M −$3.16M '24 Q1 24-05-07 ▲13.4% $36.02M −$9.23M '24 Q2 24-08-06 ▲4.4% $32.81M −$4.85M '24 Q3 24-11-12 ▲19.1% $40.78M $3.66M '24 Q4 25-02-27 ▲12.2% $38.90M $2.63M '25 Q1 25-05-06 ▲3.3% $37.20M −$2.38M '25 Q2 25-08-08 ▲16.5% $38.21M −$17.50M '25 Q3 25-11-04 ▼0.5% $40.59M −$2.95M '25 Q4 26-02-26 ▼10.8% $34.71M −$8.11M '26 Q1 26-05-11 LATEST ▲1.3% $37.67M −$5.49M '26 Q2 26-08-10
Earnings call
FY26 · Q2
2026-08-10
Heron Therapeutics, Inc. (HRTX) Q2 2026 Earnings Call Transcript
Cautious tone Cinvanti Brand Competition Acute Care Franchise Growth Balance Sheet / Hercules Amendment
Revenue
$37.67M
▲ 1.3% YoY
Diluted EPS
$-0.03
Gross margin
69.3%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY26 · Q1
2026-05-11
Heron Therapeutics, Inc. (HRTX) Q1 2026 Earnings Call Transcript
Positive tone Crosslink / Ignite Partnership Oncology / Sinvanti Acute Care Portfolio Growth
Revenue
$34.71M
▼ 10.8% YoY
Diluted EPS
$-0.04
▼ 500% YoY
Gross margin
69.4%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q4
2026-02-26
Heron Therapeutics, Inc. (HRTX) Q4 2025 Earnings Call Transcript
Confident tone Acute care franchise momentum No Pain Act reimbursement awareness PONV consensus guidelines
Revenue
$40.59M*
▼ 0.5% YoY
Gross margin
72.6%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-11-04
Heron Therapeutics, Inc. (HRTX) Q3 2025 Earnings Call Transcript
Confident tone Acute care growth (ZYNRELEF and APONVIE) CINVANTI stability PONV guidelines inclusion
Revenue
$38.21M
▲ 16.5% YoY
Diluted EPS
$-0.10
Gross margin
68.8%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-08-08
Heron Therapeutics, Inc. (HRTX) Q2 2025 Earnings Call Transcript
Confident tone ZYNRELEF commercial performance ZYNRELEF reimbursement and access APONVIE growth
Revenue
$37.20M
▲ 3.3% YoY
Diluted EPS
$-0.02
Gross margin
73.5%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-05-06
Heron Therapeutics, Inc. (HRTX) Q1 2025 Earnings Call Transcript
Confident tone APONVIE adoption in hospitals ZYNRELEF growth and market expansion CINVANTI / oncology franchise performance
Revenue
$38.90M
▲ 12.2% YoY
Diluted EPS
$0.01
Gross margin
78.3%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-02-27
Heron Therapeutics, Inc. (HRTX) Q4 2024 Earnings Call Transcript
Confident tone ZYNRELEF Growth and Inflection CINVANTI Competition and Pricing Risk CrossLink Partnership
Revenue
$40.78M*
▲ 19.1% YoY
Gross margin
74.9%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-11-12
Heron Therapeutics, Inc. (HRTX) Q3 2024 Earnings Call Transcript
Confident tone ZYNRELEF Growth Drivers (VAN, NOPAIN, CrossLink) CINVANTI Recovery and 340B Opportunity APONVIE Commercial Trajectory
Revenue
$32.81M
▲ 4.4% YoY
Diluted EPS
$-0.03
Gross margin
71.2%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-08-06
Heron Therapeutics, Inc. (HRTX) Q2 2024 Earnings Call Transcript
Confident tone ZYNRELEF label expansion and catalysts CrossLink partnership and sales force expansion Vial Access Needle (VAN) PDUFA
Revenue
$36.02M
▲ 13.4% YoY
Diluted EPS
$-0.06
Gross margin
70.8%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-05-07
Heron Therapeutics, Inc. (HRTX) Q1 2024 Earnings Call Transcript
Confident tone CrossLink partnership and sales force expansion ZYNRELEF label expansion and product performance Vial Access Needle (VAN) device development
Revenue
$34.67M
▲ 17.1% YoY
Diluted EPS
$-0.02
Gross margin
75.6%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2024-03-12
Heron Therapeutics, Inc. (HRTX) Q4 2023 Earnings Call Transcript
Confident tone Vial Access Needle and Prefilled Syringe development ZYNRELEF growth and label expansion No Pain Act and reimbursement
Revenue
$34.23M*
▲ 14% YoY
Gross margin
71.1%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q3
2023-11-14
Heron Therapeutics, Inc. (HRTX) Q3 2023 Earnings Call Transcript
Revenue
$31.43M
▲ 18.4% YoY
Diluted EPS
$-0.17
Gross margin
42.1%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q2
2023-08-14
Heron Therapeutics, Inc. (HRTX) Q2 2023 Earnings Call Transcript
Revenue
$31.76M
▲ 15% YoY
Diluted EPS
$-0.35
Gross margin
36.5%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q1
2023-05-11
Heron Therapeutics, Inc. (HRTX) Q1 2023 Earnings Call Transcript
Revenue
$29.61M
▲ 26.3% YoY
Diluted EPS
$-0.27
Gross margin
43.1%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q3
2022-11-08
Heron Therapeutics, Inc. (HRTX) Q3 2022 Earnings Call Transcript
Revenue
$26.56M
▲ 14.3% YoY
Diluted EPS
$-0.38
Gross margin
44.6%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q2
2022-08-09
Heron Therapeutics, Inc. (HRTX) Q2 2022 Earnings Call Transcript
Revenue
$27.63M
▲ 23.1% YoY
Diluted EPS
$-0.55
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q1
2022-05-09
Heron Therapeutics, Inc. (HRTX) Q1 2022 Earnings Call Transcript
Revenue
$23.46M
▲ 17.2% YoY
Diluted EPS
$-0.63
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q4
2022-02-28
Heron Therapeutics, Inc. (HRTX) Q4 2021 Earnings Call Transcript
Revenue
$20.66M*
▲ 0.2% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY21 · Q3
2021-11-03
Heron Therapeutics, Inc. (HRTX) Q3 2021 Earnings Call Transcript
Revenue
$23.23M
▲ 16.4% YoY
Diluted EPS
$-0.51
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q4
2021-01-11
Heron Therapeutics, Inc. (HRTX) Q4 2020 Earnings Call
Revenue
$20.61M
▼ 41.3% YoY
Gross margin
54.4%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY19 · Q4
2020-01-13
Heron Therapeutics, Inc. (HRTX) Q4 2019 Earnings Call
Revenue
$35.08M
▲ 21.6% YoY
Gross margin
54.8%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Showing 1–21 of 21 webcasts
Key facts CIK 818033 CUSIP 427746102 13F (30d) 2 filings 2 filers Visit website Investor relations